Home » GPC'S SATRAPLATIN WELL-TOLERATED IN PHASE I STUDY
GPC'S SATRAPLATIN WELL-TOLERATED IN PHASE I STUDY
GPC Biotech has reported that its lead drug satraplatin, being tested for cancer, was well-tolerated in a Phase I clinical study among 17 patients with advanced solid tumors.
Of the 17 patients studied, seven had hormone-refractory prostate cancer, and had received Taxotere, a chemotherapy treatment for some types of cancer, including breast, prostate and non-small cell lung cancer.
Satraplatin is in a Phase III trial for second-line hormone refractory prostate cancer and in clinical studies for other cancers.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May